AVR stock forecast, quote, news & analysis
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function... Show more
Why Anteris Technologies Global (AVR) Stock Is Down -25% in the Last 30 Days
Key Takeaways
- AVR shares fell roughly 25% over the last 30 days, declining from about $7.71 to near $5.79, extending a broader multi-month pullback.
- The stock is down approximately 30% over the last three months after peaking near $9.83 in mid-August.
- The decline occurred despite positive clinical milestones, including German regulatory clearance for the pivotal PARADIGM trial and favorable 30-day EMBARK data presented at TCT 2026.
- Anteris remains pre-commercial, and its valuation is heavily tied to the binary outcome of the roughly 1,000-patient PARADIGM trial for its DurAVR transcatheter heart valve.
- Analysts remain broadly constructive with a consensus price target near $14, though estimates were trimmed and notable insider selling was reported over the period.
- For more detail on valuation and expectations, review Anteris Technologies' Price Targets, Earnings, and Forecast pages.
- Explore how Trending AI Robots track momentum and trading opportunities across thousands of tickers.
Anteris Technologies Global (AVR) Company Overview and Market Position
Anteris Technologies Global Corp. is a clinical-stage structural heart company focused on treating aortic stenosis, a potentially life-threatening narrowing of the aortic valve. Its lead asset, the DurAVR Transcatheter Heart Valve (THV), is a single-piece, biomimetic valve built with the company's proprietary ADAPT tissue technology and delivered using its ComASUR balloon-expandable delivery system. The company is headquartered in Toowong, Australia, with U.S. operations in Eagan, Minnesota, and is dual-listed on Nasdaq and the ASX under the ticker AVR.
The company is pre-commercial: its revenue remains minimal while it invests heavily in clinical development. The investment thesis centers on the PARADIGM pivotal trial, a prospective, randomized study comparing DurAVR head-to-head against commercially available transcatheter aortic valve replacement (TAVR) valves from incumbents such as Edwards Lifesciences (EW) and Medtronic (MDT). A key validation came in January 2026, when Medtronic made a roughly $90 million strategic equity investment as part of a larger capital raise.
Anteris Technologies Global (AVR) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AVR declined from a closing price of approximately $7.71 in early October to near $5.79, a drop of roughly 25%. The move was broad-based and steady rather than driven by a single event, with the shares trading lower through most of October before additional weakness in early November.
The quarterly picture is similar but larger in magnitude. From a level of about $8.28 at the start of August, the stock has fallen roughly 30%. Shares reached an intraday peak near $9.83 in mid-August before reversing lower. The stock now trades well below its 52-week high of $11.06 but remains above its 52-week low of $3.30.
What Drove AVR Stock Price in the Last 30 Days
Notably, the 30-day decline occurred alongside a series of positive company-specific developments. In mid-October, Cantor Fitzgerald reiterated an Overweight rating with a $15 price target, citing DurAVR's hemodynamic performance. Later in October, Anteris received full regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices (BfArM) to enroll patients in the PARADIGM trial, expanding the study's European footprint. In late October, the company also reported favorable 30-day clinical and hemodynamic results for the medium-size DurAVR valve from its EMBARK study at the TCT 2026 conference.
Despite these milestones, the shares repriced lower as investors weighed several offsetting factors. Consensus fiscal 2026 revenue estimates were reduced by roughly 16% in mid-October, and the average analyst price target was trimmed to about $14. Reports also flagged approximately $25.2 million in insider selling over the trailing three months. Because Anteris generates little revenue, much of its enterprise value reflects the unproven DurAVR franchise, making the stock sensitive to shifts in risk appetite and to the binary nature of the pivotal trial outcome.
What Drove AVR Stock Performance Over the Last Quarter
The quarterly decline reflects a broader repricing of a pre-commercial asset rather than any single news event. Over the past three months, Anteris advanced its clinical strategy, including treating its first U.S. patients in the PARADIGM trial, securing CMS reimbursement to support site activation, and obtaining French and German regulatory clearances. The company's cash position of roughly $257 million provides a multi-year runway relative to its quarterly operating cash outflow of about $20.8 million.
At the same time, investors appeared to weigh the stock's elevated valuation against its limited revenue base, ongoing cash burn, estimate revisions, and reported insider selling. With the company's outlook tied closely to PARADIGM's eventual readout, the shares have been volatile and trended lower through the quarter even as the underlying clinical program progressed.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-driven trading bots. While Tickeron offers hundreds of bots that trade thousands of tickers, only the top-performing and most relevant strategies appear in this section. The bots vary by strategy, timeframe, and performance metrics, giving users a way to compare automated approaches across different market conditions. For traders and investors interested in systematic, data-driven signals, the page provides a focused starting point to review what is currently trending on the platform.
AVR Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape AVR's trajectory in the near term. The company's fiscal third-quarter results are expected in mid-November, with consensus estimates pointing to roughly $2.7 million in revenue and a continued net loss. Beyond earnings, investors are likely to monitor PARADIGM trial enrollment progress and any additional regulatory clearances, which directly influence the timeline to potential commercialization.
Cash runway and financing strategy also matter, given the company's pre-commercial profile and operating losses. Competitive positioning against established TAVR leaders Edwards Lifesciences (EW) and Medtronic (MDT), as well as any changes to analyst price targets or institutional positioning, could further influence sentiment. As always, this information is provided for educational purposes and does not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AVR sees its Stochastic Oscillator ascending out of oversold territory
On October 29, 2026, the Stochastic Oscillator for AVR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 16 instances where the indicator left the oversold zone. In 15 of the 16 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AVR's RSI Indicator exited the oversold zone, 5 of 6 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on AVR as a result. In 23 of 24 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for AVR just turned positive on October 28, 2026. Looking at past instances where AVR's MACD turned positive, the stock continued to rise in 11 of 12 cases over the following month. The odds of a continued upward trend are 90%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVR advanced for three days, in 92 of 104 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for AVR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. AVR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.206) is normal, around the industry mean (4.142). P/E Ratio (-2.918) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (238.095) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices